Reuters logo
BRIEF-Jazz Pharmaceuticals announces positive results of JZP-110 study
April 26, 2017 / 8:46 PM / 7 months ago

BRIEF-Jazz Pharmaceuticals announces positive results of JZP-110 study

April 26 (Reuters) - Jazz Pharmaceuticals Plc

* Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness

* Says expect to submit JZP-110 nda for excessive sleepiness in obstructive sleep apnea and narcolepsy in late 2017

* Jazz Pharmaceuticals - most commonly reported AEs in study generally consistent with those observed in phase 2 clinical studies evaluating JZP-110

* Says JZP-110 75 mg dose reached statistical significance on co-primary endpoint of mwt

* Says JZP-110 75 mg dose did not reach statistical significance on co-primary endpoint of ess

* Jazz Pharmaceuticals - there was one patient with two saes on JZP-110 that were considered not treatment related as assessed by investigator Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below